Lysergic Acid Diethylamide (LSD) in Palliative Care

Inclusion Criteria: * Age ≥ 22 years. * Advanced or End-stage fatal disease of any cause with a life expectancy ≥ 12 weeks and ≤ 2 years * Sufficient understanding of the study procedures and risks associated with the study. * Participants must be willing to adhere to the study procedures and sign the consent form. * Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration. * Participants must complete an actual "Emergency Medical Directive" * Participants with central nervous system (CNS) involvement of cancer are eligible if the following apply: * treated and stable CNS lesion(s) OR untreated but asymptomatic/stable lesions, defined as clinically and/or radiologically stable for ≥ 4 weeks before screening * no seizures within ≥ 4 weeks; if on antiepileptic medication: stable dose ≥ 4 weeks and no relevant drug-drug interactions expected * no requirement for high-dose corticosteroids, defined as ≤10 mg prednisone equivalent per day on a stable or decreasing dose * no leptomeningeal metastases * no concomitant therapeutic anticoagulation Exclusion Criteria: * Life expectancy \< 12 weeks * Known hypersensitivity to LSD * Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period. * Current use of a potent drug CYP2D6 inhibitor * Women who are pregnant or nursing or intend to become …